# of Displayed Technologies: 20 / 43

Applied Category Filter (Click To Remove): Oncology


Categories

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Tracking Breast Tissue Tumor Cavity after Lumpectomy
TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications
Approximately 40% of women diagnosed with breast cancer undergo a lumpectomy procedure. Approximately 170,000 lumpectomie are performed each yaer in the United States. Typically, this operation is followed by radiation therapy to ensure there are no remaining cancerous cells in the region. It is t…
  • College: College of Engineering (COE)
  • Inventors: Metzler, Sandra; Elisha, Deji; Evans, Izzy; Fedro, Joseph; Krakovsky, Mia; Sherry, Adam; Skoracki, Roman
  • Licensing Officer: Zinn, Ryan

Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males. The Need Despite the crucial role of androgen receptors (AR) in HCC progress…
  • College: College of Pharmacy
  • Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
  • Licensing Officer: Schultz, Teri

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Taysavang, Panya

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Optimum target sequence of siRNAs for cleavage
TS-062615 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…
  • College: College of Arts & Sciences
  • Inventors: Nakanishi, Kotaro
  • Licensing Officer: Willson, Christopher

ISG20 makes tiny RNA on AGOs
TS-062614 — The Need: Unlock the mysteries of RNA-mediated gene regulation with groundbreaking technology that delves into the uncharted realm of tiny RNAs (TyRNAs) shorter than 18 nucleotides. Conventional analysis techniques have overlooked these crucial elements due to technical challenges, leaving a gap in …
  • College: College of Arts & Sciences
  • Inventors: Nakanishi, Kotaro
  • Licensing Officer: Willson, Christopher

Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
  • Licensing Officer: Schworer, Adam

Noninvasive Biodosimetry Technology for Radiation Exposure Detection
TS-062556 — The Need: Noninvasive Biodosimetry Technology for Radiation Exposure Detection Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require …
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Jacob, Naduparambil; Morder, Courtney
  • Licensing Officer: Willson, Christopher

Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%. The Need Despite extensive efforts, there has been no s…
  • College: College of Medicine (COM)
  • Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
  • Licensing Officer: Schultz, Teri

Preventative Human T-cell leukemia virus type 1 vaccine
TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…
  • College: College of Veterinary Medicine
  • Inventors: Panfil, Amanda; Green, Patrick; Niewiesk, Stefan
  • Licensing Officer: Dahlman, Jason "Jay"

Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been shown to be responsible for increased oxygenation and enhanced radiation response. However, papaverine is also a phosphodiesterase 10A (PDE10A) inhibitor and its…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
  • Licensing Officer: Schultz, Teri

Generation of T cell-specific CXCR3 Transgenic mouse
TS-062320 — The Need: Addressing Susceptibility to Cutaneous Leishmaniasis Cutaneous leishmaniasis, caused by the intracellular parasite Leishmania major and transmitted by sand flies, poses a significant threat to susceptible populations. This disfiguring disease results in large skin lesions, impacting both …
  • College: College of Arts & Sciences
  • Inventors: Satoskar, Abhay; Oghumu, Steve
  • Licensing Officer: Willson, Christopher

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

Show More Technologies

Loading icon